Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ESM-inflammasome inhibitor
- Development stage
- Preclinical
- Lead developer
- Chroma Therapeutics
- Modality
- Small Molecules
01
Overview
ESM-inflammasome inhibitor is a preclinical small molecule developed by Macrophage Pharma for the treatment of liver diseases, specifically non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The drug utilizes the company's proprietary Engineered Small Molecule (ESM™) technology, which is designed to selectively target and accumulate within macrophages. By inhibiting the NLRP3 (nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3) inflammasome specifically in macrophage populations, the drug aims to modulate macrophage-driven inflammation and fibrosis, which are key drivers in the progression of NASH.
- Other names
- ESM-NLRP3 inhibitorESM-NLRP-3 inhibitorESM-NLRP 3 inhibitorMacrophage Pharma NLRP3 inhibitor
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on ESM-inflammasome inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ESM-inflammasome inhibitor.